Role of Methylprednisolone for Covid-19 Patients Admitted to a Tertiary Care Hospital

Authors

  • Komal Arshad Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Zill e Humayun Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Sultan Mehmood Kamran Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Raheel Ifikhar Combined Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Ali Yousaf Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Usman Sajid Combined Military Hospital, Jhelum/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v72i6.6602

Keywords:

Acute respiratory distress syndrome, COVID-19, Cytokine release storm, Methylprednisolone

Abstract

Objective: To determine the role of Methylprednisolone in managing COVID-19 patients.

Study Design: Cross-sectional study.

Place and Duration of Study: Pakistan Emirates Military Hospital (PEMH), Rawalpindi Pakistan, from Jan to Feb 2021.

Methodology: This study was carried out at the Department of Medicine. Medical records of all moderate, severe and critical COVID-19 patients admitted and receiving Methylprednisolone were reviewed. Methylprednisolone was used in all patients at doses 0.-2 mg per kg.

Results: A total of 200 cases were included. The most common presenting symptoms were cough (77.5%), fever (67.5%) and shortness of breath (63.5%). Most patients (85%) presented within the first week of their illness. One or more comorbidities were present in 75% of patients. Most common being hypertension in 70(35%) and diabetes mellitus in 63(31.5%).Complications seen in the study were Cytokine release storm 92(46%) and acute respiratory distress syndrome 44(22%). The median time for initiation of corticosteroid therapy was 4 hours (range 1-96 hours). Overall survival (OS) in the study was 83.5%. OS for patients with moderate, severe and critical diseases was 97.8%, 86.2% and 62%, respectively (p<0.001).
Conclusion: Corticosteroids are useful in COVID-19-admitted patients and provide excellent survival outcomes.
Keywords: Acute respiratory distress syndrome, COVID-19, Cytokine release storm, Methylprednisolone.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

30-12-2022

How to Cite

Arshad, K., Humayun, Z. e, Kamran, S. M., Ifikhar, R., Yousaf, A., & Sajid, M. U. (2022). Role of Methylprednisolone for Covid-19 Patients Admitted to a Tertiary Care Hospital. Pakistan Armed Forces Medical Journal, 72(6), 2041–44. https://doi.org/10.51253/pafmj.v72i6.6602

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 > >>